Here, the authors fuse IL-2 with an NKDG2 binding domain, and show that it induces IL-2 signalling selectively in NKG2D+ cells, delaying tumour growth in mice without the side effects of conventional IL-2 therapy. The gene discussed is KLRK1; the disease is neoplasm.